Nippon Shinyaku Co., Ltd. (NPNKF)
NPNKF Stock Price Chart
Explore Nippon Shinyaku Co., Ltd. interactive price chart. Choose custom timeframes to analyze NPNKF price movements and trends.
NPNKF Company Profile
Discover essential business fundamentals and corporate details for Nippon Shinyaku Co., Ltd. (NPNKF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
3 Sept 2021
Employees
2.21K
CEO
Toru Nakai
Description
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
NPNKF Financial Timeline
Browse a chronological timeline of Nippon Shinyaku Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 5 Feb 2026
Upcoming earnings on 11 Nov 2025
Earnings released on 7 Aug 2025
EPS came in at $0.85 surpassing the estimated $0.58 by +47.06%, while revenue for the quarter reached $274.41M , missing expectations by -1.27%.
Earnings released on 8 May 2025
EPS came in at $0.41 surpassing the estimated $0.22 by +81.73%, while revenue for the quarter reached $267.56M , beating expectations by +1.62%.
Dividend declared on 8 May 2025
A dividend of $0.43 per share was announced, adjusted to $0.43.
Dividend declared on 8 May 2025
A dividend of $0.43 per share was announced, adjusted to $0.43. The dividend will be paid on 1 Dec 2025.
Earnings released on 7 Feb 2025
EPS came in at $1.15 surpassing the estimated $0.84 by +37.07%, while revenue for the quarter reached $267.04M , missing expectations by -3.84%.
Earnings released on 13 Nov 2024
EPS came in at $0.63 surpassing the estimated $0.55 by +14.52%, while revenue for the quarter reached $279.68M , beating expectations by +9.60%.
Earnings released on 7 Aug 2024
EPS came in at $0.95 surpassing the estimated $0.54 by +75.42%, while revenue for the quarter reached $243.63M , beating expectations by +5.67%.
Earnings released on 10 May 2024
EPS came in at $0.18 falling short of the estimated $0.25 by -28.12%, while revenue for the quarter reached $234.19M , missing expectations by -0.86%.
Dividend declared on 10 May 2024
A dividend of $0.41 per share was announced, adjusted to $0.42. The dividend was paid on 30 Jun 2025.
Dividend declared on 10 May 2024
A dividend of $0.43 per share was announced, adjusted to $0.42. The dividend was paid on 5 Dec 2024.
Earnings released on 9 Feb 2024
EPS came in at $0.83 surpassing the estimated $0.75 by +11.39%, while revenue for the quarter reached $281.74M , beating expectations by +5.32%.
Earnings released on 30 Sept 2023
EPS came in at $0.74 surpassing the estimated $0.61 by +20.98%, while revenue for the quarter reached $242.91M , beating expectations by +1.03%.
Earnings released on 30 Jun 2023
EPS came in at $0.90 surpassing the estimated $0.61 by +48.35%, while revenue for the quarter reached $256.10M , beating expectations by +2.51%.
Dividend declared on 11 May 2023
A dividend of $0.41 per share was announced, adjusted to $0.42. The dividend was paid on 28 Jun 2024.
Dividend declared on 11 May 2023
A dividend of $0.41 per share was announced, adjusted to $0.42. The dividend was paid on 5 Dec 2023.
Earnings released on 31 Mar 2023
EPS came in at $0.02 falling short of the estimated $0.20 by -92.12%, while revenue for the quarter reached $258.53M , beating expectations by +11.35%.
Earnings released on 10 Feb 2023
EPS came in at $0.84 surpassing the estimated $0.59 by +42.78%, while revenue for the quarter reached $298.99M , beating expectations by +11.21%.
Earnings released on 10 Nov 2022
EPS came in at $0.73 surpassing the estimated $0.58 by +25.73%, while revenue for the quarter reached $245.64M , missing expectations by -29.26%.
Earnings released on 9 Aug 2022
EPS came in at $0.92 surpassing the estimated $0.58 by +57.29%, while revenue for the quarter reached $262.05M , beating expectations by +6.44%.
Earnings released on 11 May 2022
EPS came in at $0.05 falling short of the estimated $0.12 by -58.77%, while revenue for the quarter reached $255.69M , missing expectations by -3.53%.
Dividend declared on 11 May 2022
A dividend of $0.43 per share was announced, adjusted to $0.39. The dividend was paid on 30 Jun 2023.
Dividend declared on 11 May 2022
A dividend of $0.39 per share was announced, adjusted to $0.39. The dividend was paid on 5 Dec 2022.
Earnings released on 10 Feb 2022
EPS came in at $0.78 surpassing the estimated $0.54 by +42.65%, while revenue for the quarter reached $301.25M , beating expectations by +7.41%.
Earnings released on 10 Nov 2021
EPS came in at $0.55 surpassing the estimated $0.36 by +54.41%, while revenue for the quarter reached $274.40M .
Earnings released on 10 Aug 2021
EPS came in at $1.66 surpassing the estimated $1.20 by +38.33%, while revenue for the quarter reached $370.32M .
Earnings released on 14 May 2021
EPS came in at $0.76 falling short of the estimated $0.85 by -10.13%, while revenue for the quarter reached $271.84M .
Dividend declared on 14 May 2021
A dividend of $0.48 per share was announced, adjusted to $0.40. The dividend was paid on 30 Jun 2022.
Dividend declared on 14 May 2021
A dividend of $0.46 per share was announced, adjusted to $0.35. The dividend was paid on 3 Dec 2021.
Earnings released on 8 Feb 2021
EPS came in at $0.99 surpassing the estimated $0.71 by +39.30%, while revenue for the quarter reached $329.23M .
Earnings released on 5 Nov 2020
EPS came in at $0.32 falling short of the estimated $0.64 by -50.31%, while revenue for the quarter reached $264.34M .
Dividend declared on 13 May 2020
A dividend of $0.45 per share was announced, adjusted to $0.45. The dividend was paid on 30 Jun 2021.
Dividend declared on 13 May 2020
A dividend of $0.46 per share was announced, adjusted to $0.46. The dividend was paid on 4 Dec 2020.
NPNKF Stock Performance
Access detailed NPNKF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.